CR6491A - HIV IMMUNOGENIC COMPOSITIONS AND METHODS - Google Patents

HIV IMMUNOGENIC COMPOSITIONS AND METHODS

Info

Publication number
CR6491A
CR6491A CR6491A CR6491A CR6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A
Authority
CR
Costa Rica
Prior art keywords
hiv
immunogenic compositions
antigen
mammal
methods
Prior art date
Application number
CR6491A
Other languages
Spanish (es)
Inventor
B Moss Ronald
Original Assignee
Inmune Response Corp
Abr Llc
Acumer Investigacion Desarrollo S L
Antonio Jose De Jesus De San Juan Bosco Echevarria Parres
Dystar Textilfarben Gmbh Y Co Deutschland Kg
Eco Flora S A
John Larry Sanders
Ranka Seema Ajay
Sanofi Aventis
Smithjkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmune Response Corp, Abr Llc, Acumer Investigacion Desarrollo S L, Antonio Jose De Jesus De San Juan Bosco Echevarria Parres, Dystar Textilfarben Gmbh Y Co Deutschland Kg, Eco Flora S A, John Larry Sanders, Ranka Seema Ajay, Sanofi Aventis, Smithjkline Beecham Corp filed Critical Inmune Response Corp
Publication of CR6491A publication Critical patent/CR6491A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención ofrece composiciones inmugénicas que incrementan los niveles de B- quimiocina en un mamífero.Las composiciones inmugénicas contienen un antígeno de VIH, una mólecula de ácido nucleico aislada que contiene una secuencia inmunoestimuladora (ISS) y un adyuvnate. El antígeno de VIH puede ser un virus de VIH entero muerto sin la proteina de envoltura externa gp120. Alternativamente, el antígeno de VIH puede ser un virus de VIH entero muerto, o bien un antígeno p24. Se proporciona también un método para inhibir el SIDA, mediante el incremento de la producción de B-quimiciona en el mamífero mediante la administración al mamífero de una composición inmunogénica que contiene un antígeno de VIH, una molécula de ácido nucleico aislada que contiene una secuencia inmunoestimuladora (ISS) y un adyuvante.The invention offers immunogenic compositions that increase levels of B-chemokine in a mammal. Immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule that contains an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a dead whole HIV virus without the outer envelope protein gp120. Alternatively, the HIV antigen can be a dead whole HIV virus, or a p24 antigen. A method for inhibiting AIDS is also provided by increasing the production of B-chemocyte in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence. (ISS) and an adjuvant.

CR6491A 1999-05-06 2001-10-25 HIV IMMUNOGENIC COMPOSITIONS AND METHODS CR6491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13276299P 1999-05-06 1999-05-06
US15066799P 1999-08-25 1999-08-25

Publications (1)

Publication Number Publication Date
CR6491A true CR6491A (en) 2005-05-31

Family

ID=26830710

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6491A CR6491A (en) 1999-05-06 2001-10-25 HIV IMMUNOGENIC COMPOSITIONS AND METHODS

Country Status (8)

Country Link
EP (1) EP1176978A2 (en)
AP (1) AP1891A (en)
AU (1) AU4992900A (en)
BR (1) BR0010323A (en)
CA (1) CA2372960C (en)
CR (1) CR6491A (en)
OA (1) OA11937A (en)
WO (1) WO2000067787A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ATE464907T1 (en) 1999-02-17 2010-05-15 Csl Ltd IMMUNOGENIC COMPLEXES AND METHODS RELATING THEM
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU5821000A (en) * 1999-06-29 2001-01-31 Smithkline Beecham Biologicals (Sa) Vaccine
DE60131430T2 (en) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services OLIGODE OXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE REACTION
AU2002231336B2 (en) 2000-12-27 2007-06-28 Surefire Medical, Inc. D/B/A Trisalus Life Sciences Immunomodulatory polynucleotides and methods of using the same
SG152045A1 (en) * 2001-01-26 2009-05-29 Immune Response Corp Inc Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
US8114418B2 (en) 2001-06-21 2012-02-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—IV
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
CN1604795B (en) 2001-08-17 2010-05-26 科勒制药股份公司 Combinatorial motif immunostimulatory oligopeptides with increased activity
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
JP2005532067A (en) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド Nucleic acid composition for stimulating immune response
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN1753687A (en) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Application of CPG oligonucleotide in the treatment of hepatitis C virus infection
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
ES2381309T3 (en) 2002-12-23 2012-05-25 Dynavax Technologies Corporation Sequence of immunostimulatory oligonucleotides and methods for using them
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN101291691A (en) * 2003-08-28 2008-10-22 免疫反应公司 Immunogenic HIV compositions and related methods
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
KR101251707B1 (en) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
EP3456316A1 (en) 2011-07-06 2019-03-20 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
CN103781470A (en) 2011-07-06 2014-05-07 诺华股份有限公司 Oil-in-water emulsions that contain nucleic acids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP4101888B2 (en) * 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Also Published As

Publication number Publication date
EP1176978A2 (en) 2002-02-06
AP1891A (en) 2008-09-23
WO2000067787A3 (en) 2001-04-26
AP2001002300A0 (en) 2001-12-31
OA11937A (en) 2006-04-12
AU4992900A (en) 2000-11-21
CA2372960C (en) 2006-03-28
WO2000067787A2 (en) 2000-11-16
BR0010323A (en) 2002-01-08
CA2372960A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
CR6491A (en) HIV IMMUNOGENIC COMPOSITIONS AND METHODS
NO20023829D0 (en) Proteosome influenza vaccine
CO5680456A2 (en) COMPOSITIONS OF VACCINES THAT INCLUDE LIPOOLIGOSACARIDS OF IMMUNOTIPE L2 AND / OR L3 FROM LGTB-NEISSERIA MINIGITIDIS
ES2129386T1 (en) INFLUENZA VACCINE.
EA200001030A1 (en) OBTAINING CAPSULES AND TABLETS BY QUICKLY DISSOLVED EFAVIRENZ USING SUPERDESINTEGRATORS
DE59913046D1 (en) INFLUENZA VIRUS VACCINE COMPOSITION
BR0107679A (en) Outer membrane vesicle (omv) vaccine comprising neisseria meningitidis serum group b outer membrane proteins
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
ATE331026T1 (en) ANTIGEN-LABLED NON-INFECTIOUS RETROVIRUS-LIKE PARTICLES
ES534896A0 (en) AN IMMUNOGENIC COMPOSITION ADMINISTRABLE BY ROUTE
AR050102A1 (en) HIV FUSION POLIPEPTIDES FOR AIDS PREVENTION AND / OR TREATMENT
BR0114036A (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method for detecting HIV-induced antibodies
MX9306841A (en) UREASE BASED VACCINE AGAINST HELICOBACTER INFECTION IN MAMMALS.
AR041880A1 (en) IMMUNOGEN COMPOSITION
MXPA02005639A (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions.
ATE144143T1 (en) ARTIFICIAL VACCINE AGAINST AIDS VIRUS
BR0009485A (en) Method and compositions for preventing or reducing HIV infection by using leucine aminopeptidase inhibitors
PT1326635E (en) PHARMACEUTICAL COMPOSITION FOR IMMUNIZATION AGAINST AIDS
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
ZA200107072B (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV.
PA8551701A1 (en) PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN
CY1107446T1 (en) Anthelmintic Compositions
NO20050396L (en) Adjuvant viral particle
ES2195169T3 (en) VACCINES AGAINST CALMIDIES AND IMMUNOGENIC COMPOSITIONS CONTAINING AN EXTERNAL MEMBRANE ANTIGEN AND METHODS FOR PREPARATION.
ES2421543T3 (en) Method for the preparation of PRRS viruses and proteins, and diagnostic test kits for detection

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)